ADK Finance

DIAGNOS Announces Extension of Stock Warrants Exercise Period

Published August 13, 2025 at 04:01 PM

BROSSARD, Quebec, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence (AI), announces that it intends to extend the exercise period of an aggregate of 1,414,286 stock warrants (each a “Warrant”) issued as part of a non-brokered private placement of units initially announced on February 27, 2024. The Warrants initial exercise period is set to expire on August 27, 2025.

Related Questions

How will extending the warrant exercise period affect dilution risk for existing shareholders? What is the current market price of ADK relative to the warrant exercise price, and does the extension increase the likelihood of warrant exercises? Will the extended exercise window attract new institutional interest or affect the stock's liquidity? How does this warrant extension compare to similar actions taken by other TSX Venture biotech companies? What are the implications for the company's cash flow if the warrants are exercised after the extension? Could the extension signal management's confidence in near‑term share price appreciation? How might this announcement impact short‑term trading sentiment and volatility in ADK's stock? Is there any change in the terms or conditions of the warrants beyond the exercise period extension? What is the potential impact on the company's valuation multiples if the warrants are exercised? How does the extended warrant period align with the company's upcoming product milestones or AI technology rollouts?